What is Axoft?
Axoft operates at the intersection of biotechnology and advanced neural engineering. The company specializes in the development of scalable, bio-inspired implants designed to facilitate long-term, high-fidelity communication with the human nervous system. By prioritizing biocompatibility and signal integrity, Axoft aims to transform clinical outcomes for patients suffering from neurological conditions, effectively redefining the standard of care in neuro-prosthetics and individual health monitoring. Its market position is bolstered by a robust intellectual property portfolio and a clear roadmap for clinical translation, distinguishing it from traditional medical device manufacturers.
How much funding has Axoft raised?
Axoft has raised a total of $63M across 2 funding rounds:
Angel/Seed
$8M
Series A
$55M
Angel/Seed (2022): $8M with participation from Amino Capital, Alumni Ventures, The Engine, and Decent Capital
Series A (2026): $55M led by Hillhouse, Charoen Pokphand Group, Alumni Ventures, and Gaorong Capital
Key Investors in Axoft
Hillhouse
Hillhouse is a full life-cycle private equity firm, investing for the long term across opportunities in the healthcare, business services, consumer, and industrials sectors.
Charoen Pokphand Group
Charoen Pokphand Group is a Thai multinational conglomerate specializing in food production and telecommunications, promoting sustainable development and responsible practices.
Amino Capital
Amino Capital is a global venture capital firm based in Palo Alto, specializing in investments that leverage data moats and network effects across Frontier Tech and AI.
What's next for Axoft?
With the infusion of this latest capital, Axoft is poised to transition from early-stage research into rigorous clinical validation phases. The strategic focus will likely center on scaling manufacturing capabilities to meet the demands of upcoming human trials while simultaneously expanding its R&D team to explore new applications for its neural interface platform. As the company navigates the complexities of regulatory approval and clinical integration, the support from its diverse investor base—ranging from life-cycle private equity firms to specialized frontier tech venture funds—will be instrumental in navigating the path toward commercialization and long-term market leadership in the neuro-tech sector.
See full Axoft company page
